Treatment Landscape of Patients with HER2+ Early Breast Cancer: an Overview

Overview

Journal Ecancermedicalscience

Date 2025 Jan 16

PMID 39816391

Authors

Frederic Ivan L Ting

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most common malignancy in terms of incidence and is the leading cause of cancer deaths among women worldwide. In the Philippines, 33,079 new cases of breast cancer were documented in 2020 comprising 17.5% of all new cancer diagnoses. With a rate of 27 deaths per 100,000 people, the Philippines is the frontrunner in Asia for breast cancer mortality. HER2/neu-positive breast cancer, a more aggressive subtype associated with poorer survival outcomes, is present in about 23.5%. Fortunately, the emergence of HER2-targeted therapies has considerably improved disease-free survival and overall survival. This article reviews the most recent data in the HER2+ early breast cancer space.

References

OShaughnessy J, Sousa S, Cruz J, Fallowfield L, Auvinen P, Pulido C . Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study. Eur J Cancer. 2021; 152:223-232. DOI: 10.1016/j.ejca.2021.03.047. View

von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G . Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017; 377(2):122-131. PMC: 5538020. DOI: 10.1056/NEJMoa1703643. View

Gianni L, Pienkowski T, Im Y, Roman L, Tseng L, Liu M . Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2011; 13(1):25-32. DOI: 10.1016/S1470-2045(11)70336-9. View

von Minckwitz G, Huang C, Mano M, Loibl S, Mamounas E, Untch M . Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2018; 380(7):617-628. DOI: 10.1056/NEJMoa1814017. View

Denduluri N, Somerfield M, Chavez-MacGregor M, Comander A, Dayao Z, Eisen A . Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2020; 39(6):685-693. DOI: 10.1200/JCO.20.02510. View

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N . DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016; 22(20):5097-5108. DOI: 10.1158/1078-0432.CCR-15-2822. View

Nitz U, Gluz O, Christgen M, Grischke E, Augustin D, Kuemmel S . De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ±.... Ann Oncol. 2017; 28(11):2768-2772. DOI: 10.1093/annonc/mdx494. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

10.

Burstein H, Curigliano G, Thurlimann B, Weber W, Poortmans P, Regan M . Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021; 32(10):1216-1235. PMC: 9906308. DOI: 10.1016/j.annonc.2021.06.023. View

11.

Eiger D, Agostinetto E, Saude-Conde R, de Azambuja E . The Exciting New Field of HER2-Low Breast Cancer Treatment. Cancers (Basel). 2021; 13(5). PMC: 7957750. DOI: 10.3390/cancers13051015. View

12.

Martin M, Ting F . To Chemo or Not to Chemo… That Is the Question. JCO Glob Oncol. 2023; 9:e2300164. PMC: 10581605. DOI: 10.1200/GO.23.00164. View

13.

Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R . Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013; 24(9):2278-84. DOI: 10.1093/annonc/mdt182. View

14.

Gradishar W, Moran M, Abraham J, Abramson V, Aft R, Agnese D . NCCN Guidelines® Insights: Breast Cancer, Version 4.2023. J Natl Compr Canc Netw. 2023; 21(6):594-608. DOI: 10.6004/jnccn.2023.0031. View

15.

Genuino A, Chaikledkaew U, Guerrero A, Reungwetwattana T, Thakkinstian A . Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines. BMC Health Serv Res. 2019; 19(1):874. PMC: 6873585. DOI: 10.1186/s12913-019-4715-8. View

16.

Gutierrez C, Schiff R . HER2: biology, detection, and clinical implications. Arch Pathol Lab Med. 2011; 135(1):55-62. PMC: 3242418. DOI: 10.5858/2010-0454-RAR.1. View

17.

Shao Z, Pang D, Yang H, Li W, Wang S, Cui S . Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial. JAMA Oncol. 2019; 6(3):e193692. PMC: 6813591. DOI: 10.1001/jamaoncol.2019.3692. View

18.

Wu T, Lee J . Promoting Breast Cancer Awareness and Screening Practices for Early Detection in Low-Resource Settings. Eur J Breast Health. 2019; 15(1):18-25. PMC: 6385717. DOI: 10.5152/ejbh.2018.4305. View

19.

Chan A, Moy B, Mansi J, Ejlertsen B, Holmes F, Chia S . Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. Clin Breast Cancer. 2020; 21(1):80-91.e7. DOI: 10.1016/j.clbc.2020.09.014. View

20.

Ting F . The Road Less Traveled: Serving the Underserved. J Clin Oncol. 2020; 38(22):2597-2598. DOI: 10.1200/JCO.18.01925. View